October 2015 | Urologists in Cancer Care

Tasquinimod Discontinuation in mCRPC Discussed at 2015 ECC

September 30, 2015

Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naïve metastatic castration-resistant prostate cancer.

x